Sopheon* (SPE): Interims: value and growth opportunity (CORP) | OptiBiotix* (OPTI): US product launch of LP-LDL (CORP) | Utilitywise* (UTW): In line with recent expectations (CORP)
24 Aug 2017
Morning Note
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note
- Published:
24 Aug 2017 -
Author:
Andrew Darley | Guy Hewett | Mark Brewer | Cavendish Research -
Pages:
5
Sopheon* (SPE): Interims: value and growth opportunity (CORP) | OptiBiotix* (OPTI): US product launch of LP-LDL (CORP) | Utilitywise* (UTW): In line with recent expectations (CORP)